TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07355075: A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

Sponsor: Turn Therapeutics · Phase: PHASE2/PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 190 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,072,320

Rescue Site Savings

+$6,641,436

Unlock Full NCT07355075 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07355075 Rescue Dossier →